Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ibsa farmaceutici italia s.r.l via martiri di cefalonia, 2 26900 lodi (lo) (italiË) - levothyroxinenatrium 5-water 175 µg/stuk samenstelling overeenkomend met ; levothyroxine 153 µg/stuk - capsule, zacht - gelatine (e 441) ; gelatine, gehydrolyseerd ; glycerol (e 422) ; glycerol 85 per cent (e 422) ; water, gezuiverd, - levothyroxine sodium

Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ibsa farmaceutici italia s.r.l via martiri di cefalonia, 2 26900 lodi (lo) (italiË) - levothyroxinenatrium 5-water 200 µg/stuk samenstelling overeenkomend met ; levothyroxine 174,8 µg/stuk - capsule, zacht - gelatine (e 441) ; gelatine, gehydrolyseerd ; glycerol (e 422) ; glycerol 85 per cent (e 422) ; water, gezuiverd, - levothyroxine sodium

Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ibsa farmaceutici italia s.r.l via martiri di cefalonia, 2 26900 lodi (lo) (italiË) - levothyroxinenatrium 5-water 25 µg/stuk samenstelling overeenkomend met ; levothyroxine 21,9 µg/stuk - capsule, zacht - gelatine (e 441) ; gelatine, gehydrolyseerd ; glycerol (e 422) ; glycerol 85 per cent (e 422) ; water, gezuiverd, - levothyroxine sodium

Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ibsa farmaceutici italia s.r.l via martiri di cefalonia, 2 26900 lodi (lo) (italiË) - levothyroxinenatrium 5-water 50 µg/stuk samenstelling overeenkomend met ; levothyroxine 43,7 µg/stuk - capsule, zacht - gelatine (e 441) ; gelatine, gehydrolyseerd ; glycerol (e 422) ; glycerol 85 per cent (e 422) ; water, gezuiverd, - levothyroxine sodium

Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ibsa farmaceutici italia s.r.l via martiri di cefalonia, 2 26900 lodi (lo) (italiË) - levothyroxinenatrium 5-water 75 µg/stuk samenstelling overeenkomend met ; levothyroxine 65,6 µg/stuk - capsule, zacht - gelatine (e 441) ; gelatine, gehydrolyseerd ; glycerol (e 422) ; glycerol 85 per cent (e 422) ; water, gezuiverd, - levothyroxine sodium

Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ibsa farmaceutici italia s.r.l via martiri di cefalonia, 2 26900 lodi (lo) (italiË) - levothyroxinenatrium 5-water 88 µg/stuk samenstelling overeenkomend met ; levothyroxine 76,9 µg/stuk - capsule, zacht - gelatine (e 441) ; gelatine, gehydrolyseerd ; glycerol (e 422) ; glycerol 85 per cent (e 422) ; water, gezuiverd, - levothyroxine sodium

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ibsa farmaceutici italia s.r.l. - diclofenac epolamine 12,93 mg/g - eq. diclofenac 10 mg/g - gel - 1 % - diclofenac epolamine 12.93 mg/g - diclofenac

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ibsa farmaceutici italia s.r.l. - diclofenac epolamine 180 mg - eq. diclofenacnatrium 140 mg - pleister - 140 mg - diclofenac epolamine 180 mg - diclofenac

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ibsa farmaceutici italia s.r.l. - diclofenac epolamine 180 mg - eq. diclofenacnatrium 140 mg - pleister - 140 mg - diclofenac epolamine 180 mg - diclofenac

Europska Unija - nizozemski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.